Abstract
Oxidative stress, linked to Abeta-lipid interactions, plays a pathogenetic role in Alzheimers disease. We investigated modifications of lipid peroxidation products in plasma of 52 AD patients, 42 healthy controls and 16 patients with amyotrophic lateral sclerosis, a neurodegenerative disease where oxidative stress also plays a pathogenetic role. Final lipid peroxidation products were measured in plasma by thiobarbituric acid reactive substances (TBARS) assay before and after ex vivo oxidative stress catalysed by copper. There were no significant changes at basal conditions, but after copperinduced oxidation TBARS levels were higher in AD patients (19.0 μM ± 2.2) versus both controls (5.2 μM ± 0.8, p < 0.001) and ALS patients (7.6 M ± 2.1, p < 0.01). Stimulated TBARS levels were significantly higher in mild and moderate AD (p < 0.0001) with respect to controls, but not in severe AD patients, with a significant inverse correlation between disease severity and lipid peroxidation (p < 0.005, r2=0.21). Treatment of a subgroup (13) of mild and moderate AD patients with vitamin C and E for three months decreased plasma lipoperoxidation susceptibility by 60%. Thus, oxidative stress, expressed as ex vivo susceptibility to lipid peroxidation, appears to be an early phenomenon, probably related to AD pathogenetic mechanisms.
Keywords: alzheimers disease, oxidative stress, tbars, beta amyloid, copper
Current Alzheimer Research
Title: Increased Susceptibility to Plasma Lipid Peroxidation in Alzheimer Disease Patients
Volume: 1 Issue: 2
Author(s): Carmen Galbusera, Maurizio Facheris, Fulvio Magni, Gloria Galimberti, Gessica Sala, Lucia Tremolada, Valeria Isella, Franca Rosa Guerini, Ildebrando Appollonio, Marzia Galli-Kienle and Carlo Ferrarese
Affiliation:
Keywords: alzheimers disease, oxidative stress, tbars, beta amyloid, copper
Abstract: Oxidative stress, linked to Abeta-lipid interactions, plays a pathogenetic role in Alzheimers disease. We investigated modifications of lipid peroxidation products in plasma of 52 AD patients, 42 healthy controls and 16 patients with amyotrophic lateral sclerosis, a neurodegenerative disease where oxidative stress also plays a pathogenetic role. Final lipid peroxidation products were measured in plasma by thiobarbituric acid reactive substances (TBARS) assay before and after ex vivo oxidative stress catalysed by copper. There were no significant changes at basal conditions, but after copperinduced oxidation TBARS levels were higher in AD patients (19.0 μM ± 2.2) versus both controls (5.2 μM ± 0.8, p < 0.001) and ALS patients (7.6 M ± 2.1, p < 0.01). Stimulated TBARS levels were significantly higher in mild and moderate AD (p < 0.0001) with respect to controls, but not in severe AD patients, with a significant inverse correlation between disease severity and lipid peroxidation (p < 0.005, r2=0.21). Treatment of a subgroup (13) of mild and moderate AD patients with vitamin C and E for three months decreased plasma lipoperoxidation susceptibility by 60%. Thus, oxidative stress, expressed as ex vivo susceptibility to lipid peroxidation, appears to be an early phenomenon, probably related to AD pathogenetic mechanisms.
Export Options
About this article
Cite this article as:
Galbusera Carmen, Facheris Maurizio, Magni Fulvio, Galimberti Gloria, Sala Gessica, Tremolada Lucia, Isella Valeria, Guerini Rosa Franca, Appollonio Ildebrando, Galli-Kienle Marzia and Ferrarese Carlo, Increased Susceptibility to Plasma Lipid Peroxidation in Alzheimer Disease Patients, Current Alzheimer Research 2004; 1 (2) . https://dx.doi.org/10.2174/1567205043332171
DOI https://dx.doi.org/10.2174/1567205043332171 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Current Therapy of Drugs in Amyotrophic Lateral Sclerosis
Current Neuropharmacology IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry The Interplay between G-quadruplex and Transcription
Current Medicinal Chemistry A Novel Physico-Chemical Property Based Model for Studying the Effects of Mutation on the Aggregation of Peptides
Protein & Peptide Letters Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Selenium and Clinical Trials: New Therapeutic Evidence for Multiple Diseases
Current Medicinal Chemistry A New Hypothesis of Pathogenesis Based on the Divorce between Mitochondria and their Host Cells: Possible Relevance for Alzheimers Disease
Current Alzheimer Research Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Subject Index To Volume 3
Current Alzheimer Research Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
Current Cancer Drug Targets Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Aluminum Induced Immunoexcitotoxicity in Neurodevelopmental and Neurodegenerative Disorders
Current Inorganic Chemistry (Discontinued)